Galectin-3 levels in patients hospitalized for decompensated heart failure

Simple item page
dc.contributor.authorRossel, Victor
dc.contributor.authorDiaz Toro, Felipe
dc.contributor.authorVerdejo, Hugo
dc.contributor.authorConcepcion, Roberto
dc.contributor.authorSepulveda, Luis
dc.contributor.authorCastro, Pablo
dc.contributor.authorLuis Vukasovic, Jose
dc.contributor.authorBernales, Angie
dc.contributor.authorRepresentacion Departmento Insufic
dc.date.accessioned2024-01-10T12:05:39Z
dc.date.available2024-01-10T12:05:39Z
dc.date.issued2017
dc.description.abstractGalectin-3 (Gal-3) is a mediator of myocardial fibrosis involved in cardiac remodeling and a potential new prognosis marker in heart failure (HF). Aim: To measure Gal-3 at the moment of discharge in patients hospitalized for HF and its association with different variables. Material and Methods: Patients hospitalized for decompensated HF from four hospitals between August 2014 and March 2015, were included. Demographic, clinical and laboratory variables were recorded at the time of admission. At discharge, a blood sample was withdrawn to measure Gal-3 and brain natriuretic propeptide (Pro-BNP). Patients were separated in two groups, according to the level of Gal-3 (using a cutoff value of 17.8 ng/mL), comparing clinical and laboratory values between groups. Results: We included 52 patients with HF aged 70 17 years (42% females). Functional capacity was III-IV in 46% of patients and the ejection fraction was 34.9 13.4%. Pro-BNP values at discharge were 5,323 8,665 pg/mL. Gal-3 values were 23.8 16.6 ng/mL. Sixty percent of patients had values over 17.8 ng/mL. Those with elevated Gal-3 levels were older (75 16 and 62 15 years, respectively, p = 0.025) and were hypertensive in a higher proportion (90.5% and 57.1% respectively, p = 0.021). Conclusions: In patients hospitalized for HF, Gal-3 levels are higher in older and hypertensive subjects.
dc.fechaingreso.objetodigital2024-05-29
dc.format.extent7 páginas
dc.fuente.origenWOS
dc.identifier.doi10.4067/s0034-98872017000600734
dc.identifier.eissn0717-6163
dc.identifier.issn0034-9887
dc.identifier.pubmedidMEDLINE:29171621
dc.identifier.urihttps://doi.org/10.4067/s0034-98872017000600734
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/76046
dc.identifier.wosidWOS:000407985600007
dc.information.autorucMedicina;Castro P;S/I;100212
dc.information.autorucMedicina;Verdejo H;S/I;1001175
dc.issue.numero6
dc.language.isoes
dc.nota.accesoContenido completo
dc.pagina.final740
dc.pagina.inicio734
dc.publisherSOC MEDICA SANTIAGO
dc.revistaREVISTA MEDICA DE CHILE
dc.rightsacceso abierto
dc.subjectBiomarkers
dc.subjectGalectin-3
dc.subjectHeart Failure
dc.subjectQUALITY-OF-LIFE
dc.subjectGENERAL-POPULATION
dc.subjectNATIONAL REGISTRY
dc.subjectPROGNOSTIC VALUE
dc.subjectMARKER
dc.subjectFIBROSIS
dc.subjectEPIDEMIOLOGY
dc.subjectPERSPECTIVE
dc.subjectDEPRESSION
dc.subjectBIOMARKERS
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleGalectin-3 levels in patients hospitalized for decompensated heart failure
dc.typeartículo
dc.volumen145
sipa.codpersvinculados100212
sipa.codpersvinculados1001175
sipa.indexWOS
sipa.indexScopus
sipa.trazabilidadCarga SIPA;09-01-2024
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Galectin-3 levels in patients hospitalized for decompensated heart failure.pdf
Size:
296.95 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Artículos de revistas